NEW YORK – Fujirebio and Sysmex announced on Tuesday that they have entered into an agreement to collaborate on the development of immunoassays.
Since 2020, Fujirebio has been developing dedicated reagents for Sysmex's Automated Immunoassay System HISCL-Series through its subsidiaries. Under the new agreement, the companies will explore a variety of potential collaborations, including research and development, production, clinical development, and sales and marketing, the firms said in a statement.
Fujirebio and Sysmex will move forward into the execution phase of the deal by the end of March 2024, the two Japan-based firms said.